GPP
VTGN icon

Great Point Partners’s VistaGen Therapeutics VTGN Stock Holding History

Great Point Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-674,075
Closed -$2.03M – 33
2024
Q3 		$2.03M Sell
674,075
-855,263
-56% -$2.92M 0.6% 29
2024
Q2 		$5.32M Sell
1,529,338
-329,397
-18% -$1.43M 1.02% 27
2024
Q1 		$9.81M Hold
1,858,735
– – 1.53% 26
2023
Q4 		$9.55M Buy
+1,858,735
New +$7.03M 1.63% 23

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Point Partners's VTGN Position: Q4 2024 in Review

Great Point Partners sold out of VistaGen Therapeutics (VTGN) in Q4 2024, closing a stake of 674,075 shares — an estimated $2.03M sold.

Great Point Partners first reported a position in VTGN in Q4 2023 and held it in 4 quarters. The position peaked at $9.81M in Q1 2024. 54 funds tracked by Wall St. Rank hold VTGN as of Q4 2024.

  • Great Point Partners reported no remaining VistaGen Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Great Point Partners sold 674,075 VistaGen Therapeutics shares in Q4 2024, an estimated $2.03M.
  • Great Point Partners first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 4 quarters.
  • Great Point Partners's VistaGen Therapeutics position peaked at $9.81M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2024.

Based on Great Point Partners's 13F filing for Q4 2024, filed 14 Feb 2025.